Patient-centered care has been getting a lot of attention as the healthcare industry focuses on the Triple Aim of delivering better health outcomes, improving patient experience, and reducing the cost of care. In that vein, the Louis W. Sullivan Institute for Healthcare Innovation recently released 6 guiding principles of patient-centered care.
Patient-centered care has been getting a lot of attention as the healthcare industry focuses on the Triple Aim of delivering better health outcomes, improving patient experience, and reducing the cost of care. In that vein, the Louis W. Sullivan Institute for Healthcare Innovation recently released 6 guiding principles of patient-centered care.
The principles were created by the Sullivan Institute’s Patient Experience Council, a collective body of ePatients and eAdvocates, and presented at WEDI-Con 2014 in Reston, VA.
“As healthcare stakeholders explore strategies to deliver more patient-centric care, products and services, we see these Guiding Principles serving as the next step to ensuring that the patient engagement strategies being considered result in patient-experience centered outcomes,” Kym Martin, MBA, CNC, CFT, co-chair of The Sullivan Institute’s Patient Experience Council, said in a statement.
The principles expand upon the Institute of Medicine’s definition of patient-centered care in an attempt to aid stakeholders to strengthen patient-centered efforts and include:
According to the Patient Experience Council, patient-centered care and these 6 guiding principles can not only improve quality, safety, and patient satisfaction, but also healthcare professional satisfaction, which reduces turnover and burnout.
“I believe that the principles being released today by our Patient Experience Council will help provide a framework for how organizations should orient their efforts in order to prepare for the future landscape of healthcare,” WEDI President and Chief Executive Officer Devin Jopp, EdD, said.
See full explanations for the guiding principles here: http://bit.ly/1rrCCpl
FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy
November 22nd 2024The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.
Read More